Skip to main content
AmigoFish

Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

From BioSpace · · 19 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.

Back to BioSpace · Report a problem